Programme

10:00-11:30 (EST)

Session I: Genomics and epigenomics of MM:
Chairs: Gareth Morgan & Ola Landgren

• 1q and the pathogenesis of MM; Samir Parekh
• Mutational signatures and the evolution of MM; Francesco Maura
• Insights from functional genomics in MM; Constantine Mitsiades
• Evolving insights into the t(4;14); Gareth Morgan
• The clinical and molecular relationship of MGUS and MM; Ola Landgren

Panel Discussion: Chairs and invited speakers

11:30-12:55

Session II: Novel Targets
Chairs: Ken Anderson & Maria V Mateos

• Strategies targeting super enhancers in MM; Wee Joo
• Update on ubiquitin ligases, Celmods and new IMiDs; Ken Anderson
• Anti-BCMA and other immunoconjugates; Suzanne Trudel
• Targeting MCL1 and BCL2 inhibition; Larry Boise
• Therapeutic trials in MGUS and SMM; Maria V Mateos
• PIKfyve- a novel target in Myeloma; Keith Stewart
• Endpoints and therapy options for amyloidosis; Suzanne Lentzsch

Panel Discussion: Chairs and invited speakers

10:00-11:30

Session III: Evaluating new therapies
Chairs: Ivan Borrello & Irene Ghobriel

• The MM niche, quiescence and BMP6; Sarah Gooding
• Single cell analysis of myeloma and its microenvironment; Irene Ghobrial
• Pre-clinical disease models of MM; Marta Chiesi
• The current therapeutic standard for MM; Pieter Sonneveld
• Molecular and clinical definitions of high-risk MM; Leif Bergsagel
• Genetic changes associated with relapse; Jonathan Keats

Panel Discussion: Chairs and invited speakers  

11:30-13:00

Session IV: T-cell engagement strategies:
Chairs: Hermann Einsele & Yi Lin

• Clinical data and trial data on bi-specific antibodies for MM; Hermann Einsele
• Clinical data and trial update of anti-BCMA CAR-Ts; Yi Lin
• Optimizing and manufacturing CAR-T constructs; Eric Smith
• Mechanisms of resistance to immune oncology drugs; Leo Rasche

Panel Discussion: Chairs and invited speakers